Biomarkers of response to therapy in oesophago-gastric cancer

Gut

Volumn 58, Issue 1, 2009, Pages 127-143

  Fareed, K R ^a   Kaye, P ^a   Soomro, I N ^a   Ilyas, M ^a   Martin, S ^a   Parsons, S L ^b   Madhusudan, S ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; CALDESMON; CAPECITABINE; DEOXYURIDINE PHOSPHATE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; P21 ACTIVATED KINASE; PROTEIN BAX; PROTEIN C JUN; PROTEIN P53; SURVIVIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; URIDINE PHOSPHORYLASE; ANTINEOPLASTIC ANTIMETABOLITE; DNA; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSFORMATION; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; ESOPHAGUS TUMOR; GENETICS; METABOLISM; METHODOLOGY; STOMACH TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA REPAIR; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 58249090429     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.155861     Document Type: Review

References (117)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049-53.
2. Blot WJDS, Kneller RW. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287-9.
3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17:2-9.
4. Wanebo HJ, Kennedy KB, Chmiel J. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583-92.
5. Scartozzi M, Galizia E, Freddari F, et al. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004; 30:451-9.
6. Law SY, Fok M, Cheng SW, Wong J. A comparison of outcome after resection for squamous cell carcinomas and adenocarcinomas of the esophagus and cardia. Surg Gynecol Obstet 1992; 175:107-12.
7. Lerut TDLP, Coosemans W, Van Raemdonck 0, et al. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992; 216:583-90.
8. Orringer MB. Multimodality therapy for esophageal carcinoma - an update. Chest 1993; 103:406S-9S.
9. Lieberman MDSC, Bleckner S, Butt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thoracic Cardiovas Surg 1995; 109:130-8.
10. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20.
11. Bancewicz J, Clark PI, Smith DB, et al. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-33.
12. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73:2680-6.
13. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98:1521-30.
14. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24:4692-8.
15. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-65.
16. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8:797-805.
17. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21:4604-10.
18. Kim MK, Ryu JS, Kim SB, et al. Value of complete metabolic response by (18jF-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43:1385-91.
19. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008; 14:2012-8.
20. Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med 2005; 11:503-11.
21. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6:1653-64.
22. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
23. An Q, Robins P, Lindahl T, et al. 5-Fluorouracil incorporated into DNA is excised by the Smugl DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007; 67:940-5.
24. Venturini M. Rational development of capecitabine. Eur J Cancer 2002; 38(Suppl 2):3-9.
25. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anti- Cancer Drugs 2004; 15:85-106.
26. Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006; 94:281-6.
27. Lu JW, Gao CM, Wu JZ, et al. Polymorphism in the 3'- untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 2006; 51:155-60.
28. Liao Z, Liu H, Swisher SG, et al. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 64:700-8.
29. Ott K, Vogelsang H, Marton N, et al. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumorrelated survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 2006: 119:2885-94.
30. Matzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-16.
31. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14:176-82.
32. Ichikawa W, Takahashi T, Suto K, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006; 119:1927-33.
33. Napierakki R, Ott K, Kremer M, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 2005; 11:3025-31.
34. Ishikawa Y, Kubota T, Otani Y, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91:105-12.
35. Terastuma M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002; 22:761-8.
36. Kodera Y, Ito S, Fujiwara M, et al. Gene expression of 5- fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett 2007; 252:307-13.
37. Langer R, Specht K, Becker K, et al. Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. Am J Clin Pathol 2007; 126:191-7.
38. Josai MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11:2215-21.
39. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005; 200:336-44.
40. Langer R, Specht K, Becker K, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005; 11:7462-9.
41. Yah KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82:1626-31.
42. Fukuda H, Takiguchi N, Koda K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 2006: 24:235-41.
43. Alexander HR, Grem JL, Hamilton JM, et al. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J Sci Am 1995; 1:49-54.
44. Koizumi W, Saigenji K, Nakamaru N, et al. Prediction of response to 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet- derived endothelial cell growth factor. Oncology 1999; 56:215-22.
45. Nishina T, Hyodo I, Miyaike J, et al. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine. Eur J Cancer 2004; 40:1566-71.
46. KJknyama S, Inada T, Shimizu K, et al. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 2001;21:2149-53.
47. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
48. Masada H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203:1175-80.
49. Gossage L Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1I in cancer. Cancer Treat Rev 2007; 33:565-77.
50. Stddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003: 22:7265-79.
51. Gossage L, Madhusudan S. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007; 11:361-80.
52. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006: 106:253-76.
53. Reardon JT, Sancar A. Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005; 79:183-235.
54. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004: 73:39-85.
55. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 2008: 18:27-47.
56. Deeks ED, Scott LJ. Docetaxel: In gastric cancer. Drugs 2007; 67:1893-901.
57. Farhat FS. A general review of the role of irinotecan ICPT111 in the treatment of gastric cancer. Med Oncol 2007; 24:137-46.
58. Wei J, Lin B, Zou Z, et al. ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy. J Clin Oncol 2007; 25(18S|:2512.
59. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006: 24:1883-91.
60. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24:3789-98.
61. Zarate RN, Arias F, Bandres E, et al. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 2006; 12:6032-6.
62. Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified F0LF0X regimen. Br J Cancer 2008; 98:1398-402.
63. Matsubara J, Nishina T, Yamada Y, et al. Impacts of excision repair cross-complementing gene 1 IERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008; 98:832-9.
64. Matzger R, Danenberg K, Leichman CG. et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-6.
65. Wareecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10:3794-9.
66. Leichman L, Lawrence D, Leichman CG, et al. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother 2006; 18:514-24.
67. Miyazono F, Metzger R, Wamecke-Eberz U, et al. Quantitative cerbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004; 91:666-72.
68. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxallplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:504-9.
69. Km MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008; 44:54-60.
70. Noguchi T, Shibata T, Fumoto S. et al. DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol 2002; 9:1017-22.
71. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8:121-32.
72. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2:277-68.
73. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-23.
74. Nakamura M, Tsuji N, Asanuma K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 2004; 95:44-51.
75. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95:92-5.
76. Wamecke-Eberz U, Hokita S, Xi H, et al. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005; 13:1241-6.
77. Kang SY, Han JH, Lee KJ, et al. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 2007; 13:4146-53.
78. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59:198-204.
79. Mao XY, Wang XG, Lv XJ, et al. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol 2007; 13:3466-71.
80. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11:8341-7.
81. Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998; 4:1469-74.
82. Nagashima F, Boku N, Ohtsu A, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005; 35:714-9.
83. Cascinu S, Graziano F, Del Ferro E, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83:1917-22.
84. Nakata B, Chung KH, Ogawa M, et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 1998; 28:595-8.
85. Bataille F, Rummele P, Dietmaier W, et al. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 2003; 56:286-92.
86. Okumura H, Natsugoe S, Matsumoto M, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005; 92:284-9.
87. Sarbia M, Ott N, Puhringer-Oppermann F, et al. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer 2007; 97:1404-8.
88. Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radial Oncol Biol Phys 2003; 57:1323-7.
89. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9:6461-8.
90. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24:748-54.
91. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-95.
92. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
93. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22:6549-56.
94. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nature Rev Cancer 2002; 2:38-47.
95. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-lalpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110:838-44.
96. Boku N, Ohtsu A, Nagashima F, et al. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. Jpn J Clin Oncol 2007; 37:509-14.
97. Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86:552-7.
98. Imdahl A, Bognar G, Schulte-Monting J, et al. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002; 21:657-63.
99. Kulke MH, Odze RD, Mueller JD, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 2004; 127:1579-86.
100. Kruh GD, Zeng H, Rea PA, et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001; 33:493-501.
101. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54.
102. Gotoh M, Takiuchi H, Kawabe S, et al. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol 2007; 37:652-7.
103. Scharf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24:236-44.
104. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007; 7:367-74.
105. Akatsu Y, Saikawa Y, Kubota T, et al. Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. Cancer Sci 2007; 98:707-15.
106. van 't Veer U, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452:564-70.
107. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452:571-9.
108. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452:553-63.
109. Luthra MG, Ajani JA, Izzo J, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007; 13:912-9.
110. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006; 24:259-67.
111. Ashida A, Boku N, Aoyagi K, et al. Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 2006; 28:1345-52.
112. Duong C, Greenawalt DM, Kowalczyk A, et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol 2007; 14:3602-9.
113. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008; 452:580-9.
114. West CM, Jones T, Price P. The potential of positron-emission tomography to study anticancer-drug resistance. Nat Rev Cancer 2004; 4:457-69.
115. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomographyguided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008; 70:2-13.
116. Ott K, Vogelsang H, Mueller J, et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003; 9:2307-15.
117. Ling FC, Leimbach N, Baldus SE, et al. HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer. Anticancer Res 2006; 26:4505-9.